- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, March 26, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by Health referenced a June 2019 contributor piece published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The contributor article, titled “The Deadly Costs of Insulin,” noted the significant price increases of insulin treatment, from $14 for 1 vial in 2001 to $275 in 2019.
A piece by Patheos spotlighted an article published on AJMC.com, titled “Mental Health Issues On the Rise Among Adolescents, Young Adults.” The article details rates of mood disorders and suicide-related outcomes that have increased significantly among adolescents and young adults, with a possible link to the rise of social media.
An article by Herald-Tribune cited a study published in the January 2021 issue of AJMC® titled “Differences in the Use of Telephone and Video Telemedicine Visits During the COVID-19 Pandemic.” The study found lower use of video vs telephone visits among older, Black, Hispanic, and Spanish-speaking patients amid the COVID-19 pandemic, driven largely by clinician and practice factors.
High-Intensity Home-Based Rehabilitation in a Medicare Accountable Care Organization
January 8th 2025High-intensity home-based rehabilitation (HIHR) may substitute for facility-based postacute rehabilitation. Patients in HIHR had better functional outcomes at lower costs than patients in facility-based care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17
January 7th 2025A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Read More
